CBI 2026 Biopharma Innovation Expo Announces Call for Cutting-Edge Roadshow Projects Across Frontier Therapeutic Areas
Jinweike Biotechnology
AAV Gene Therapy New Drug Developer
How far is your project from achieving commercialization? Is it a round of financing? A strategic partner? An opportunity to pitch to investors? Or an industry showcase that gets you noticed?
【CBI2026 Biopharmaceutical Innovation Expo】is now openly soliciting high-quality roadshow projects from research institutes, universities, and innovative enterprises worldwide. We look forward to discovering outstanding achievements with innovation and development potential, building a bridge for in-depth exchange between innovative technologies and industrial resources!
Our next collaboration may well begin with this roadshow.
Roadshow Time:September 4–5, 2026
Roadshow Venue:Suzhou International Expo Center, Hall B, Booth B107
Fields for Solicitation:Peptides/XDCs/Nucleic Acids/Small Molecules/Antibodies/CGT and Other Frontier Fields
Project Requirements:Breakthrough Projects from Preclinical to Clinical Stages
▼
Project Name
The World’s First AAV Gene Therapy Novel Drug R&D Platform Based on a Two-Plasmid Process
Roadshow Guest
Chen Lijing, COO/Vice President, Chengdu Jinweike Biotechnology Co., Ltd.
Project Introduction
The design and manufacturing of AAV gene therapy drugs present significant technical barriers. Enhancing drug safety and efficacy, improving patient accessibility, reducing costs, and expanding commercial production capacity constitute major challenges in the field of AAV gene therapy. Chengdu Jinweike Biotechnology Co., Ltd. is the world’s first AAV gene therapy new drug R&D platform led by academicians that adopts a two-plasmid process. Starting with ophthalmic diseases and neuromuscular disorders, the company is accelerating the clinical application of gene therapy drugs, substantially reducing manufacturing costs, and improving the accessibility of gene therapies to ensure that patients can afford and benefit from effective treatments. The company’s drug R&D capabilities and AAV production technology are at the leading level in China, with multiple pipeline candidates having entered Phase II clinical trials.
▼
Project Name
Application of Navigation Cell-Borne Factors (NCK) in the Treatment of Solid Tumors
Roadshow Guest
Chen Jinyin, CEO of Hangzhou Yinjie Biopharmaceutical Co., Ltd.
Project Introduction
Hangzhou Navigen Biopharmaceutical Co., Ltd. was founded under the leadership of Dr. Yang Meijia, a national-level scientist. The company is dedicated to applying cutting-edge biotechnology to address unmet clinical needs in major diseases by developing First-in-Class (FIC) and Best-in-Class (BIC) Advanced Therapy Medicinal Products (ATMPs). Navigen Biopharmaceutical currently operates two major technology platforms: NCK solid tumor therapy and recombinant protein synthetic biology. In the field of gene-edited cell therapy (CGT), the company’s core pipeline, “NCK Solid Tumor Therapy,” represents a disruptive innovation. This technology platform features broad-spectrum efficacy against solid tumors, an improved safety profile (eliminating the need for lymphodepletion), and affordability, offering hope for a cure to patients with solid tumors. It has currently entered the Investigator-Initiated Trial (IIT) stage of clinical research.
Yinjiek Biotechnology operates a 1,000 m² GMP-compliant R&D and pilot-scale platform in Hangzhou Future Sci-Tech City and a 200 m² cleanroom laboratory in Nanjing. The company has been selected for the “Leading Talent” program in Yuhang District, Hangzhou, and has received substantial support through special government funds. Yinjiek Biotechnology has established industry–academia–research collaborations with universities such as China Pharmaceutical University and Zhejiang Chinese Medical University, and conducts clinical research partnerships with institutions including Zhejiang Cancer Hospital and the General Hospital of the Eastern Theater Command. The company is also advancing the development of R&D platforms, including postdoctoral and doctoral research stations.
▼
Project Name
The World's First Mitochondria-Enhanced Mesenchymal Stem Cell Drug
Roadshow Guest
Li Yijia, Shanghai Ximaishi Biopharmaceutical Co., Ltd.
Project Introduction
Shanghai Ximaisi Biopharmaceutical Co., Ltd. specializes in mitochondrial-enhanced mesenchymal stem cell therapies for sarcopenia and pneumoconiosis. The project’s core technology is based on the team’s proprietary patents, offering advantages in high efficiency, safety, and low cost. It can more than double the average mitochondrial count of approximately 500 per mesenchymal stem cell, thereby enabling more efficient mitochondrial delivery to muscle cells. The core patent received the Silver Medal at the 2026 Geneva International Invention Exhibition, and the project was awarded a RMB 10 million provincial-level key research grant from Anhui Province, leveraging its core platform technology. Currently, the CiMSC™ technology platform has entered the clinical phase, with an investigator-initiated clinical trial underway at Nanjing Drum Tower Hospital, where enrollment of the first patient is imminent.
Ximaith leverages mitochondrial delivery technology as its platform, collaborating with institutions including Tsinghua University, Fudan University, Shanghai Jiao Tong University, Anhui University of Science and Technology, ShanghaiTech University, and Shandong Pharmaceutical University. The company has successfully achieved mitochondrial delivery and enhancement in NK cells, hepatocytes, lung epithelial cells, macrophages, neurons, and cardiomyocytes, ushering in a new era of energy metabolism-enhancing cell therapies.
▼
Project Name
In Vivo Differentiation of Stem Cells for Anti-Aging
Roadshow Guest
Cao Xin, Hainan Kangrui Biotechnology
Project Introduction
In vivo differentiation of stem cells: Compared with the expensive customized in vitro induction technology for iPSCs, this technical solution directly applies small-molecule inducers in vivo, allowing the inducers to be adapted to the individual’s internal environment, thereby facilitating the industrialization and standardization of cell therapy.
The main component of this protocol, kaempferol, repairs genes via homologous recombination. As a multi-target modulator, kaempferol addresses the tumorigenicity of stem cells in vivo. Kaempferol also acts as a Notch modulator; the Notch signaling pathway does not directly express genes but instead drives direct in vivo differentiation into the ectoderm, mesoderm, and endoderm.
Kaempferol Dosage: ≥10 μM
Second is therapeutic potential. For diseases such as amyotrophic lateral sclerosis (ALS) and depression, which lack clearly defined target organs, this technology offers a novel approach to treatment.
Third is the application threshold. Stem cell drug approval is stringent, whereas small-molecule inducers can be developed as innovative drugs, significantly lowering the barrier. Kaempferol, a compound also found in fruits and vegetables, has long had its safety profile established.
As in vivo CAR-T therapy becomes a hot investment focus, in vivo stem cell differentiation technology is also poised for development.
▼
Project Name
Dual-Target In Vivo CAR-T Therapy for Autoimmune Diseases
Roadshow Guest
Wei Lifan, Vice President of R&D, Shenzhen Enruikainuo Biotechnology Group Co., Ltd.
Project Introduction
This project is based on long-acting mRNA and actively targeted tLNP delivery technology, using CD8a VHH as the T-cell targeting ligand to design dual-target in vivo CAR-T therapy. It achieves deep depletion of B cells in mice and monkeys, including those in peripheral blood and deep tissues, thereby enabling immune reset and disease cure.
▼
Project Name
CQ-0736, A Potent Novel Polysaccharide-Drug Conjugate Targeting Pan-KRAS Mutant Tumors
Roadshow Guest
Wang Si, CEO of Suzhou Saint-Dolicon Pharmaceutical Co., Ltd.
Project Introduction
Addressing the critical clinical challenges posed by RAS mutations, which drive nearly 20% of human cancers, and the severe systemic toxicity and drug resistance associated with existing pan-RAS inhibitors, our team has developed CQ-0736—a first-in-class “Trojan horse” dual-drug polysaccharide conjugate. This project leverages the specifically hyperactivated “macropinocytosis” nutrient-scavenging mechanism in RAS-mutant tumors to achieve precise intratumoral delivery and synergistic cytotoxicity of the dual payloads, while perfectly sparing normal tissues.
Preclinical data demonstrated that CQ-0736 exhibited significant efficacy in lung cancer PDX models, achieving a 16.5-fold greater reduction in tumor volume compared to the current leading-edge drug RMC-6236, with an excellent safety profile and no evidence of drug resistance. As a disruptive innovation, these findings were successfully presented in an oral session at the 2026 AACR Annual Meeting.
▼
Project Name
Anchoring on the Discovery of Novel Targets: Pioneering the Development of First-in-Class Anti-Tumor Innovative Drugs with Dual B/T Lymphocyte Modulation
Roadshow Guest
Huang Chuanshu, Founder, CEO, CSO of Weiyi Kangze
Project Introduction
Leveraging its original research achievements, the company focuses on the development of Class I innovative drugs. Its core product, the WY series, consists of small-molecule targeted innovative drugs based on novel precision targets for anti-tumor therapy, possessing fully independent intellectual property rights. These products feature high target specificity, efficient cancer cell clearance, and an exceptional safety profile. They can effectively modulate anti-tumor immunity, the tumor immune microenvironment, and the metabolic microenvironment in tumor-bearing hosts, thereby breaking through existing bottlenecks in immunotherapy. The product pipeline covers solid tumors such as pancreatic cancer, gastric cancer, bladder cancer, liver cancer, lung cancer, and renal cell carcinoma, as well as "immunologically hot tumors" including acute myeloid leukemia, demonstrating broad clinical application prospects. The company has filed a total of seven invention patents (including three domestic patents, two PCT international patents, and two patents in the Taiwan region). In 2025, it completed two rounds of financing totaling RMB 41 million and has engaged Tigermed to prepare for the Investigational New Drug (IND) applications for its Class I innovative drugs in both China and the United States.
liyaling7723@sina.com or contact Ms. Li at 18215607723 (WeChat ID same as phone number)
Add Friend to Register
Please note "CBI Roadshow"
August 8, 2026
*The roadshow schedule will be prioritized based on the time of submission after approval.
Add Friend to Register
Please note "CBI Roadshow"
Click the forum image to learn more
